scholarly journals The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy

2021 ◽  
Vol 11 ◽  
Author(s):  
Hui Yang ◽  
Kunlun Wang ◽  
Bingxu Li ◽  
Shenglei Li ◽  
Yan Li ◽  
...  
Keyword(s):  
Egfr Mutation ◽  
Univariate Analysis ◽  
Inflammatory Biomarkers ◽  
Small Cell Lung ◽  
Prognostic Role ◽  
Stage Iiia ◽  
Trimodality Therapy ◽  
Mutation Status ◽  
Nsclc Patients

ObjectivesVarious blood inflammatory biomarkers were associated with treatment response and prognosis of non-small cell lung cancer (NSCLC) in previous studies. In this study, we retrospectively evaluated the prognostic role of pretreatment blood inflammatory biomarkers and epidermal growth factor receptor (EGFR) mutation status in stage IIIA/N2 NSCLC patients with trimodality therapy.MethodsCompletely resected stage IIIA/N2 NSCLC patients with adjuvant chemotherapy and postoperative radiotherapy (PORT) were assessed in this study. Cutoff values of blood inflammatory factors were calculated by the R package SurvivalROC of R software. SPSS Statistics software was used for survival analyses. Kaplan-Meier survival curve and log-rank test were used to compare the survival difference between every two groups. Univariate and multivariate analyses of predictive factors were performed by Cox proportional hazards regression model.ResultsThe univariate analysis showed that T stage (p=0.007), EGFR mutation status (p=0.043), lymphocyte-to-monocyte ratio (LMR) (p=0.067), and systemic immune-inflammation index (SII) (p=0.043) were significant prognostic factors of disease-free survival (DFS). In the multivariate analysis, T2 (HR=0. 885, 95% CI: 0.059-0.583, p=0.004), EGFR mutation-positive (HR=0.108, 95% CI: 0.023-0.498, p=0.004) and elevated pretreatment SII (HR=0.181, 95%CI: 0.046-0.709, p=0.014) were independently related to shorter DFS. High pretreatment neutrophil counts (HR=0.113, p=0.019) and high systemic inflammation response index (SIRI) (HR=0.123, p=0.025) were correlated with worse overall survival (OS) by the univariate analysis. In the multivariate analysis, only high pretreatment SIRI was an independent predictor for poorer OS (HR=0.025, 95% CI: 0.001-0.467, p=0.014).ConclusionsIn conclusion, we identified that high pretreatment SII and SIRI were unfavorable prognostic factors in stage IIIA/N2 NSCLC patients treated with surgery, adjuvant chemotherapy and PORT. Patients with high pretreatment SII, high pretreatment SIRI, T2, and EGFR mutation-positive may need more forceful adjuvant treatment. Further prospective studies with large-scale are needed to validate our results and identify the proper cut-off values and optimum adjuvant treatment for distinct patient population.

Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

2014 ◽  
Vol 41 (11) ◽  
pp. 2058-2065 ◽  
Author(s):  
Carlos Caicedo ◽  
Maria Jose Garcia-Velloso ◽  
Maria Dolores Lozano ◽  
Tania Labiano ◽  
Carmen Vigil Diaz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status ◽  
18F Fdg

scholarly journals Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients

2019 ◽  
Vol 53 (4) ◽  
pp. 453-458
Author(s):  
Karmen Stanic ◽  
Nina Turnsek ◽  
Martina Vrankar
Keyword(s):  
Lung Cancer ◽  
Medical Records ◽  
Disease Burden ◽  
Egfr Mutation ◽  
Tnm Classification ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Mutation Status ◽  
Nsclc Patients

Abstract Background The 8th edition of tumor node metastasis (TNM) staging system for lung cancer introduced a revision of M descriptor. The limitation of new classification to predict prognosis is its focus on anatomical extent of the disease only. Information on molecular status of the tumor significantly influences treatment response and survival; however, data addressing this issue is scarce. This report points to the impact of epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC) patients on survival in view of new M descriptors of TNM classification system. Patients and methods Medical records of 479 consecutive metastatic NSCLC patients treated between 2009 and 2011, all tested for EGFR mutations, were retrospectively reviewed. For 355 patients medical records included sufficient information to be appropriately categorized into one of the new subgroups according to the M descriptor in 8th TNM classification, of those 89 (25.1%) patients harboured EGFR mutations (EGFR-m). Results Median overall survival (mOS) of EGFR-m patients was significantly longer than mOS of patients without EGFR mutations (20.6 months vs. 8.3 months, p < 0.001). Patients with limited disease burden (M1b sub-group) had the longest mOS among EGFR wild type patients (EGFR-wt) and also among EGFR-m patients, 14.4 months and 39.2 month, respectively. In spite of widespread metastatic disease of M1c EGFR-m patients, their mOS (18.8 months) was longer than mOS of oligometastatic EGFR-wt patients (M1b), who had the lowest disease burden (14.4 months). Median follow up was 53.9 months. Conclusions Incorporation of EGFR mutation status in advanced NSCLC further differentiates survival curves of M categories in 8th TNM classification and more precisely predicts survival compared to number of metastasis or number of metastatic sites alone.

Current progress and quality of radiomic studies for predicting EGFR mutation in patients with non-small cell lung cancer using PET/CT images: a systematic review

2021 ◽  
pp. 20201272
Author(s):  
Meilinuer Abdurixiti ◽  
Mayila Nijiati ◽  
Rongfang Shen ◽  
Qiu Ya ◽  
Naibijiang Abuduxiku ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status ◽  
Pet Ct ◽  
Nsclc Patients

Objectives: To assess the methodological quality of radiomic studies based on positron emission tomography/computed tomography (PET/CT) images predicting epidermal growth factor receptor (EGFR) mutation status in patients with non-small cell lung cancer (NSCLC). Methods: We systematically searched for eligible studies in the PubMed and Web of Science datasets using the terms “radiomics”, “PET/CT”, “NSCLC”, and “EGFR”. The included studies were screened by two reviewers independently. The quality of the radiomic workflow of studies was assessed using the Radiomics Quality Score (RQS). Interclass correlation coefficient (ICC) was used to determine inter rater agreement for the RQS. An overview of the methodologies used in steps of the radiomics workflow and current results are presented. Results: Six studies were included with sample sizes of 973 ranging from 115 to 248 patients. Methodologies in the radiomic workflow varied greatly. The first-order statistics were the most reproducible features. The RQS scores varied from 13.9 to 47.2%. All studies were scored below 50% due to defects on multiple segmentations, phantom study on all scanners, imaging at multiple time points, cut-off analyses, calibration statistics, prospective study, potential clinical utility, and cost-effectiveness analysis. The ICC results for majority of RQS items were excellent. The ICC for summed RQS was 0.986 [95% confidence interval (CI): 0.898–0.998]. Conclusions: : The PET/CT based radiomics signature could serve as a diagnostic indicator of EGFR mutation status in NSCLC patients. However, the current conclusions should be interpreted with care due to the suboptimal quality of the studies. Consensus for standardization of PET/CT based radiomic workflow for EGFR mutation status in NSCLC patients is warranted to further improve research. Advances in knowledge: Radiomics can offer clinicians better insight into the prediction of EGFR mutation status in NSCLC patients, whereas the quality of relative studies should be improved before application to the clinical setting.

Association of brain metastasis in non-small cell lung cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e19081-e19081
Author(s):  
Yu Zhao ◽  
Huiqin Guo ◽  
Jiangyang Lu ◽  
David C. Christiani ◽  
Xihong Lin ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lymph Node ◽  
Brain Metastasis ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status ◽  
Node Metastasis ◽  
Younger Age ◽  
Nsclc Patients

e19081 Background: Brain metastases are the main cause of non-small cell lung cancer (NSCLC) relapse and death. However, it is difficult to predict which NSCLC patient will develop brain metastasis. We have observed and summarized the relationship between the clinical and molecular biological features including EGFR mutation status and brain metastases in a prospectively enrolled case series, and developed a multivariable model in this study. Methods: The study enrolled 184 Chinese NSCLC patients with at least 18 months follow-up period. Clinical information including age, smoking history, lymph node status, pathological stage, primary location and histological type of the tumor and EGFR (including exon 19 and 21) and KRAS mutation status were collected and analyzed. Univariate and multivariate Cox regression analysis was run to investigate risk factors of brain metastasis from these features. A risk model based on these risk factors was constructive. Results: 13.0% (24/184) patients were diagnosed as brain metastasis. EGFR mutation (P=0.026), younger age (P=0.034) and lymph node metastasis (P=0.038) were associated with brain metastasis. A Cox model based on these 3 factors was founded and the risk of brain metastasis was 1.9% (1/53), 8.3% (5/60) and 25.4 % (18/71) in low, intermediate and high risk group, respectively (P<0.001). Conclusions: EGFR mutation, younger age and lymph node metastasis are associated with brain metastasis in NSCLC patients. If confirmed in clinical trials, high risk patients may be considered for prophylactic cranial irradiation therapy in future clinical trials

Prognostic role of targeted therapy in patients with multiple-site metastases from non-small- cell lung cancer

2020 ◽  
Vol 16 (26) ◽  
pp. 1957-1967
Author(s):  
Chunliu Meng ◽  
Xingping Ge ◽  
Jia Tian ◽  
Jia Wei ◽  
Lujun Zhao
Keyword(s):  
Lung Cancer ◽  
Liver Metastases ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Prognostic Role ◽  
Adrenal Metastases ◽  
Nsclc Patients ◽  
Egfr Tkis

Aim: To evaluate the prognostic role of EGFR mutations in patients with multi-site metastases from non-small-cell lung cancer (NSCLC). Patients & methods: A total of 215 advanced NSCLC patients with multi-site metastases were included. The overall survival (OS) was the primary end point. Results: EGFR tyrosine kinase inhibitors (TKIs) significantly improved the OS in patients with brain metastases (p = 0.031) and bone metastases (p = 0.048). Meanwhile, it prolonged the OS in patients with lung or adrenal metastases, but not in patients with liver metastases. However, in patients without liver metastases, EGFR TKIs significantly improved the OS (p < 0.001). Conclusion: EGFR TKIs improved the prognosis in NSCLC patients with brain, bone, lung and adrenal metastases, but not in patients with liver metastases.

scholarly journals Erratum to: Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

2014 ◽  
Vol 41 (11) ◽  
pp. 2164-2164
Author(s):  
Carlos Caicedo ◽  
Maria Jose Garcia-Velloso ◽  
Maria Dolores Lozano ◽  
Tania Labiano ◽  
Carmen Vigil-Diaz ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Fdg Pet ◽  
Egfr Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Mutation Status ◽  
18F Fdg

scholarly journals Prognostic Role of MicroRNA Let-7 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

2020 ◽  
Author(s):  
Xiaoting Zhang ◽  
Huaning Kang ◽  
Guihong Chen ◽  
Xiaofeng Li
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Small Cell ◽  
Cochrane Library ◽  
Small Cell Lung ◽  
Prognostic Role ◽  
Nsclc Patients

Abstract BackgroundRecent studies have shown that MicroRNAs can be used as potential biomarkers to the prognosis in non-small cell lung cancer (NSCLC). Hence, we conducted this meta-analysis to evaluate the prognostic role of microRNA let-7 in NSCLC patients.MethodsPubMed, Web of Science, Medline and the Cochrane Library were searched for relevant studies. Eligible studies were met specific inclusion and exclusion criteria. Stata 15.1 was used to calculate the pooled parameters.ResultsA total of 11 studies involving 2278 NSCLC patients were included in this meta-analysis. Subgroup analyses established that the heterogeneity was connected with ethnicity and follow-up time. The results suggested that the low expression of microRNA let-7 indicates a poor overall survival rate, with a hazard ratio value of 0.99 (95% CI: 0.64-1.34, P <0.05).ConclusionsLow expression of microRNA let-7 is closely related to the poor prognosis of NSCLC, so microRNA let-7 may become a new biomarker to evaluate the prognosis of NSCLC patients.

Sign in / Sign up

Export Citation Format

Share Document